Abstract
Nesfatin-1, derived from the nucleobindin-2 gene product, is expressed in neurons located in brain centers known to be important in the central regulation of both cardiovascular function and fluid and electrolyte homeostasis. In fact the peptide colocalizes in those neurons with an impressive list of neuropeptides and neurotransmitters known to be important in the regulation of thirst, appetite and central autonomic control. We and others have demonstrated potent sympatho-stimulatory actions of nesfatin-1 in brain and the potential physiologic relevance of those effects. In addition, although nesfatin-1 was originally described as a peptide with potent anorexigenic actions in brain, effects corroborated by several groups, it is possible that the anorexigenic actions of nesfatin-1 are secondary to a primary action to reduce thirst. Progress in unraveling the importance of endogenous nesfatin-1 in cardiovascular function, or fluid and electrolyte homeostasis, has been limited due to the to date unavailability of nesfatin-1 antagonists and the fact that the receptor for nesfatin-1 remains unidentified.
Keywords: Arterial pressure, sympathetic nervous system, hypothalamus, medulla, thirst, appetite.
Current Pharmaceutical Design
Title:Cardiovascular and Antidipsogenic Effects of Nesfatin-1
Volume: 19 Issue: 39
Author(s): Gina L.C. Yosten and Willis K. Samson
Affiliation:
Keywords: Arterial pressure, sympathetic nervous system, hypothalamus, medulla, thirst, appetite.
Abstract: Nesfatin-1, derived from the nucleobindin-2 gene product, is expressed in neurons located in brain centers known to be important in the central regulation of both cardiovascular function and fluid and electrolyte homeostasis. In fact the peptide colocalizes in those neurons with an impressive list of neuropeptides and neurotransmitters known to be important in the regulation of thirst, appetite and central autonomic control. We and others have demonstrated potent sympatho-stimulatory actions of nesfatin-1 in brain and the potential physiologic relevance of those effects. In addition, although nesfatin-1 was originally described as a peptide with potent anorexigenic actions in brain, effects corroborated by several groups, it is possible that the anorexigenic actions of nesfatin-1 are secondary to a primary action to reduce thirst. Progress in unraveling the importance of endogenous nesfatin-1 in cardiovascular function, or fluid and electrolyte homeostasis, has been limited due to the to date unavailability of nesfatin-1 antagonists and the fact that the receptor for nesfatin-1 remains unidentified.
Export Options
About this article
Cite this article as:
Yosten L.C. Gina and Samson K. Willis, Cardiovascular and Antidipsogenic Effects of Nesfatin-1, Current Pharmaceutical Design 2013; 19 (39) . https://dx.doi.org/10.2174/138161281939131127142720
DOI https://dx.doi.org/10.2174/138161281939131127142720 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Platelet Tau Protein as a Potential Peripheral Biomarker in Alzheimer’s Disease: An Explorative Study
Current Alzheimer Research Nutraceuticals: Beyond the Diet Before the Drugs
Current Bioactive Compounds Synergy Between Direct Coronary Stenting Technique and Use of the Novel Thin Strut Cobalt Chromium Skylor™ Stent: the Mace in Follow Up Patients Treated with Skylor Stent [MILES Study]
Current Cardiology Reviews Smad3-Mediated Signals Showing Similarities and Differences Between Epithelial and Mesenchymal Cells in Human Chronic Liver Diseases
Current Enzyme Inhibition Overview of Murine Atherosclerosis Series
Current Drug Targets Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. Statistical Regression Modeling to Predict Diabetic Proteinuria
Current Diabetes Reviews Ethosomal Hydrogel of Raloxifene HCl: Statistical Optimization & Ex Vivo Permeability Evaluation Across Microporated Pig Ear Skin
Current Drug Delivery Cardiovascular Proteomics
Current Proteomics Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
Current Chemical Biology Glutathione Modulation and Oxidative Stress in Human Liver Slices
Current Drug Discovery Technologies Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Visit-to-visit Blood Pressure Variability and Arterial Stiffness: Which Came First: The Chicken or the Egg?
Current Pharmaceutical Design Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Validation of a Solid Phase Extraction Procedure for Identification and Quantification of Cocaine and Metabolities in Meconium Using GC/MS
Current Pharmaceutical Analysis Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research